Teladoc, Inc. (NYSE: TDOC) is the nation’s first and largest telehealth platform, delivering on-demand health care anytime, from almost anywhere via mobile devices, the Internet, secure video and phone. Teladoc provides health plans, employers, organizations and individuals with access to its network of more than 3,000 board-certified, state-licensed physicians and behavioral health professionals who provide care for a wide range of non-emergency conditions.
Recognized in June 2015 by MIT Technology Review as one of the “50 Smartest Companies,” Teladoc is transforming the access, cost and quality dynamics of health care delivery. For more information, please visit teladoc.com, twitter.com/teladoc, facebook.com/teladoc or linkedin.com/teladoc.
Ada is pioneering a new way of patient finding — meeting people at the moment they search for answers and guiding them to the right care faster.
Built by doctors and scientists, Ada’s Clinical AI is regulated as a Class IIa medical device in the EU. Our assessments are more than symptom checks — they enable partners to identify underdiagnosed patients, accelerate time-to-diagnosis, and measure real-world outcomes.
Pharma organizations use Ada to engage patients earlier in their journey and connect them to the therapies they need. Health systems and insurers leverage Ada to route patients to appropriate care and surface underutilized benefits.
With 13 million users worldwide and over 32 million assessments completed, Ada is trusted globally to transform uncertainty into action.
DermTech 2.0 provides genomic analysis of skin samples collected non-invasively using its proprietary Smart Sticker platform technology. DermTech 2.0 develops and markets products to facilitate the assessment of melanoma, including the DermTech Melanoma Test, and offers DermTech Stratum, a precision biomarker service offering for biopharmaceutical and research partners.